Spots Global Cancer Trial Database for zanubrutinib
Every month we try and update this database with for zanubrutinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma | NCT04002297 | Mantle Cell Lym... | zanubrutinib bendamustine rituximab | 60 Years - | BeiGene | |
| Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies | NCT04551963 | B-cell Malignan... | Zanubrutinib Fluconazole Diltiazem Voriconazole Clarithromycin | 18 Years - | BeiGene | |
| Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies | NCT02795182 | Lymphoma Leukemia | Zanubrutinib Tislelizumab | 18 Years - | BeiGene | |
| BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) | NCT03520920 | Marginal Zone L... Follicular Lymp... Diffuse Large B... | Zanubrutinib Rituximab | 18 Years - | BeiGene | |
| A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | NCT03740529 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... B-cell Lymphoma Small Lymphocyt... | Pirtobrutinib Venetoclax Rituximab | 18 Years - | Eli Lilly and Company | |
| Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma | NCT04899570 | Intravascular L... | Zanubrutinib Rituximab Cyclophosphamid... Epirubicin Vindesine Prednisone | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL | NCT04515238 | Chronic Lymphoi... | Bendamustine Obinutuzumab Zanubrutinib Venetoclax | 18 Years - | German CLL Study Group | |
| Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL) | NCT03206970 | Refractory Mant... Relapsed Mantle... | Zanubrutinib | 18 Years - 75 Years | BeiGene | |
| A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma | NCT06341556 | Mantle Cell Lym... Maintenance The... | Zanubrutinib | 18 Years - | Fudan University | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies | NCT02343120 | B-cell Malignan... | Zanubrutinib | 18 Years - | BeiGene | |
| A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T | NCT06167785 | Large B-cell Ly... | Tislelizumab Zanubrutinib Tislelizumab + ... | 18 Years - | University Health Network, Toronto | |
| Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL) | NCT06073821 | CLL | Sonrotoclax Zanubrutinib Venetoclax Obinutuzumab | 18 Years - | BeiGene | |
| Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL) | NCT03206970 | Refractory Mant... Relapsed Mantle... | Zanubrutinib | 18 Years - 75 Years | BeiGene | |
| A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) | NCT03162536 | Lymphoma, B-Cel... Small Lymphocyt... Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Diffuse Large B... Richter's Trans... Follicular Lymp... Marginal Zone L... | Nemtabrutinib | 18 Years - | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) | |
| Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression | NCT06005870 | Diffuse Large B... | Zanubrutinib pl... | 18 Years - 75 Years | Huazhong University of Science and Technology | |
| Zanubrutinib in Maintenance Therapy of DLBCL Patients With Initial Remission | NCT05596097 | Diffuse Large B... | Zanubrutinib | 18 Years - | LanZhou University | |
| Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma | NCT03846427 | Marginal Zone L... MZL | Zanubrutinib | 18 Years - | BeiGene | |
| Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL | NCT04705129 | Primary Mediast... EBV-Positive DL... | Zanubrutinib Tislelizumab | 18 Years - 80 Years | Ruijin Hospital | |
| Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell Lymphoma | NCT05940064 | Diffuse Large B... | Zanubrutinib, P... | 60 Years - | Shanghai Zhongshan Hospital | |
| ZR2 Followed by Immunochemotherapy in Elderly Patients With Newly-diagnosed DLBCL | NCT05290090 | Diffuse Large B... | Rituximab, Lena... | 65 Years - 85 Years | Zhejiang Cancer Hospital | |
| Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients | NCT05735834 | Splenic Margina... | Rituximab Zanubrutinib | 18 Years - | International Extranodal Lymphoma Study Group (IELSG) | |
| Prospective Clinical Study of ZPR Regimen in Relapsed/Refractory Diffuse Large B-cell Lymphoma | NCT05940051 | Diffuse Large B... | Zanubrutinib, P... | 18 Years - 80 Years | Shanghai Zhongshan Hospital | |
| Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome | NCT05873712 | Recurrent Trans... Refractory Tran... Transformed Chr... Recurrent Trans... Recurrent Trans... Refractory Tran... Refractory Tran... Refractory Tran... | Biospecimen Col... Bone Marrow Bio... Computed Tomogr... Cyclophosphamid... Fludarabine Leukapheresis Lisocabtagene M... Lymph Node Biop... Positron Emissi... Zanubrutinib | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas | NCT06350318 | Follicular Lymp... Marginal Zone L... B-Cell Lymphoma | Zanubrutinib Rituximab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors | NCT05887726 | Diffuse Large B... | Zanubrutinib Rituximab Cyclophosphamid... Epirubicin Vincristine Prednisone | 18 Years - | Liaoning Tumor Hospital & Institute | |
| ZR-CHOP in DLBCL With Specific Gene Abnormality | NCT05290337 | Diffuse Large B... | zanubrutinib | 18 Years - 75 Years | Fudan University | |
| The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years | NCT05179733 | Diffuse Large B... | six courses of ... six courses of ... | 70 Years - | Ruijin Hospital | |
| The Efficacy and Safety of ZR2 Versus R-miniCHOP in the Treatment of Unfit or Frail de Novo Diffuse Large B-cell Lymphoma Patients Aged Older Than or Equal to 70 Years | NCT05179733 | Diffuse Large B... | six courses of ... six courses of ... | 70 Years - | Ruijin Hospital | |
| Zanubrutinib and Venetoclax in CLL (ZANU-VEN) | NCT05168930 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Zanubrutinib | 18 Years - | Dana-Farber Cancer Institute | |
| A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia | NCT05979948 | Waldenström's M... | Zanubrutinib Bendamustine Rituximab | 18 Years - 75 Years | Shanghai Changzheng Hospital | |
| Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | NCT04282018 | Chronic Lymphoc... Small Lymphocyt... Follicular Lymp... Marginal Zone L... Mantle Cell Lym... Diffuse Large B... Advanced Solid ... | BGB-10188 Zanubrutinib Tislelizumab | 18 Years - | BeiGene | |
| Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL | NCT05287984 | Chronic Lymphoc... Small Lymphocyt... Newly Diagnosed | Zanubrutinib, F... Zanubrutinib, b... | 18 Years - | Institute of Hematology & Blood Diseases Hospital, China | |
| Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRL | NCT04899453 | Primary Vitreor... | Methotrexate Rituximab Zanubrutinib | 18 Years - 75 Years | Peking Union Medical College Hospital | |
| Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL | NCT06033820 | Diffuse Large B... Diffuse Large B... | ZR2-ICE | 18 Years - 75 Years | RenJi Hospital | |
| A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma | NCT05200312 | Non Hodgkin Lym... Diffuse Large B... | Zanubrutinib Lenalidomide Rituximab Cyclophosphamid... Doxorubicin Vincristine Prednisone (or ... | 18 Years - | The First Affiliated Hospital with Nanjing Medical University | |
| Zanubrutinib and Venetoclax in CLL (ZANU-VEN) | NCT05168930 | Chronic Lymphoc... Small Lymphocyt... | Venetoclax Zanubrutinib | 18 Years - | Dana-Farber Cancer Institute | |
| Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL | NCT04515238 | Chronic Lymphoi... | Bendamustine Obinutuzumab Zanubrutinib Venetoclax | 18 Years - | German CLL Study Group | |
| Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma | NCT04938297 | Central Nervous... | Rituximab, Lena... Lenalidomide, Z... Lenalidomide | 18 Years - | Henan Cancer Hospital | |
| Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas | NCT05681195 | Primary Central... Secondary Centr... Relapsed Cancer Refractory Canc... | Pemetrexed Zanubrutinib Autologous Stem... Whole Brain Rad... | 18 Years - | Baptist Health South Florida | |
| Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM) | NCT03332173 | Waldenström's M... | Zanubrutinib | 18 Years - | BeiGene | |
| Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib | NCT05068440 | Relapsed Diffus... Refractory Diff... | Zanubrutinib | 18 Years - | BeiGene | |
| Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma | NCT06029309 | Mantle Cell Lym... | Zanubrutinib Tafasitamab | 18 Years - | University of Miami | |
| MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL | NCT06367374 | Chronic Lymphoc... Small Lymphocyt... | Sonrotoclax Zanubrutinib | 18 Years - 75 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies | NCT04277637 | Mature B-Cell M... | BGB-11417 Zanubrutinib obinutuzumab | 18 Years - | BeiGene | |
| Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies | NCT04551963 | B-cell Malignan... | Zanubrutinib Fluconazole Diltiazem Voriconazole Clarithromycin | 18 Years - | BeiGene | |
| This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma | NCT06427213 | Lymphoma, Mantl... Lymphoma, Non-H... | Zanubrutinib,Ob... Zanubrutinib an... | 18 Years - | Henan Cancer Hospital | |
| Zanubrutinib Combined With R-CHOP in the Treatment of Newly Diagnosed DLBCL With p53 Protein Expression | NCT06005870 | Diffuse Large B... | Zanubrutinib pl... | 18 Years - 75 Years | Huazhong University of Science and Technology | |
| ZR-CHOP in DLBCL With Specific Gene Abnormality | NCT05290337 | Diffuse Large B... | zanubrutinib | 18 Years - 75 Years | Fudan University | |
| Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas | NCT05681195 | Primary Central... Secondary Centr... Relapsed Cancer Refractory Canc... | Pemetrexed Zanubrutinib Autologous Stem... Whole Brain Rad... | 18 Years - | Baptist Health South Florida | |
| Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies | NCT04170283 | B-cell Malignan... | Zanubrutinib Tislelizumab | 18 Years - | BeiGene | |
| Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) | NCT03824483 | Chronic Lymphoc... Small Lymphocyt... | Zanubrutinib Obinutuzumab Venetoclax | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL | NCT03740529 | Chronic Lymphoc... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... B-cell Lymphoma Small Lymphocyt... | Pirtobrutinib Venetoclax Rituximab | 18 Years - | Eli Lilly and Company | |
| A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double Expression | NCT05189197 | Diffuse Large B... | Zanubrutinib + ... | 18 Years - 80 Years | Fudan University | |
| Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma | NCT05635162 | Mantle Cell Lym... | Zanubrutinib Rituximab | 18 Years - | University College, London | |
| Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib | NCT05068440 | Relapsed Diffus... Refractory Diff... | Zanubrutinib | 18 Years - | BeiGene | |
| Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL | NCT04705129 | Primary Mediast... EBV-Positive DL... | Zanubrutinib Tislelizumab | 18 Years - 80 Years | Ruijin Hospital | |
| Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL | NCT04705129 | Primary Mediast... EBV-Positive DL... | Zanubrutinib Tislelizumab | 18 Years - 80 Years | Ruijin Hospital | |
| A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS | NCT04477291 | Acute Myeloid L... Myelodysplastic... | CG-806 | 18 Years - | Aptose Biosciences Inc. | |
| Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL | NCT04515238 | Chronic Lymphoi... | Bendamustine Obinutuzumab Zanubrutinib Venetoclax | 18 Years - | German CLL Study Group | |
| A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma | NCT06136351 | Lymphoma, Mantl... | Zanubrutinib Rituximab Bendamustin | 18 Years - | Ruijin Hospital | |
| Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's Macroglobulinemia | NCT04463953 | Waldenström Mac... | Zanubrutinib,Ix... | 18 Years - | Institute of Hematology & Blood Diseases Hospital, China | |
| BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies | NCT02569476 | B-cell Lymphoid... | Zanubrutinib Obinutuzumab | 18 Years - | BeiGene |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
